-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38

Benzinga·07/09/2025 10:55:20
Listen to the news
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.